Selinexor
- PDF / 181,323 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 67 Downloads / 131 Views
1 S
Clostridium difficile infection secondary to neutropenia: case report. In retrospective study of 437 patients with multiple myeloma, a patient [age and sex not stated] was described, who developed Clostridium difficile infection secondary to neutropenia (both grade ≥3) during treatment with selinexor for multiple myeloma [route, dosage, duration of treatment to reactions onsets and outcomes not stated]. Gavriatopoulou M, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 34: 2430-2440, No. 9, 803506878 Sep 2020. Available from: URL: http://doi.org/10.1038/s41375-020-0756-6
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
